Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Assets: 2023-2025

Historic Current Assets for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $129.5 million.

  • Artiva Biotherapeutics' Current Assets fell 13.97% to $129.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.5 million, marking a year-over-year decrease of 13.97%. This contributed to the annual value of $188.6 million for FY2024, which is 136.32% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Current Assets stood at $129.5 million, which was down 13.11% from $149.1 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Current Assets peaked at $188.6 million during Q4 2024, and registered a low of $49.7 million during Q2 2024.
  • In the last 3 years, Artiva Biotherapeutics' Current Assets had a median value of $149.1 million in 2025 and averaged $131.1 million.
  • Over the last 5 years, Artiva Biotherapeutics' Current Assets had its largest YoY gain of 199.64% in 2025, and its largest YoY loss of 13.97% in 2025.
  • Artiva Biotherapeutics' Current Assets (Quarterly) stood at $79.8 million in 2023, then skyrocketed by 136.32% to $188.6 million in 2024, then declined by 13.97% to $129.5 million in 2025.
  • Its Current Assets stands at $129.5 million for Q3 2025, versus $149.1 million for Q2 2025 and $170.0 million for Q1 2025.